Navigation Links
ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
Date:8/14/2008

BROOMFIELD, Colo., Aug. 14 /PRNewswire/ -- ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, announced today that it has appointed William R. Hiatt, MD, as Director of Clinical and Regulatory Strategy. In this newly created position, Dr. Hiatt will be responsible for developing strategic regulatory and clinical initiatives designed to support the company's lead product candidate, Gencaro(TM) (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator in late-stage development for heart failure, as well as other compounds in ARCA's pipeline.

"Dr. Hiatt is a recognized expert who knows cardiovascular medicine from virtually every angle: as researcher, physician, educator, clinician and former advisor to the U.S. Food and Drug Administration," said Richard B. Brewer, president and chief executive officer of ARCA biopharma. "He brings valuable experience and insight to ARCA as we prepare to introduce our first product and begin to educate the medical community about the benefits of genetically targeted treatment of heart failure."

"I look forward to working with the talented men and women at ARCA to bring important new solutions to heart failure patients," said Dr. William Hiatt. "By inaugurating the personalized medicine trail in the heart failure arena, ARCA is changing the way we offer treatment to patients with this serious chronic condition."

Dr. Hiatt is Professor of Medicine, Professor of Cardiovascular Research and Chief of the Section of Vascular Medicine at the University of Colorado Denver's Anschutz Medical Campus. Throughout his career, Dr. Hiatt's research has focused on developing new therapies for patients with peripheral arterial disease and understanding its pathophysiology in terms of the effects of muscle ischemia on muscle metabolism and function. Dr. Hiatt also is President of the Colorado Preventio
'/>"/>

SOURCE ARCA biopharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2

Related biology technology :

1. Ondine Biopharma Announces Second Quarter 2008 Financial Results
2. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
4. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
5. ARCA biopharma Appoints James Carr as Vice President of Marketing
6. TriCipher is First to Transfer Smart Card Level Security to Federally Approved SAFE-BioPharma(TM) Roaming Credentials
7. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
8. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
9. PacificGMP to Merge With Pacific Biopharma Group and Create Innovative US-Compliant cGMP Contract Biomanufacturing Facility in China
10. Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008
11. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)NEW YORK, Dec. 4 Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL-501, in both in vitro and animal models of human chroni
(Date:12/3/2009)SAN FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today anno
(Date:12/3/2009)NEW DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan Jiang, M.D., Ph.D.,Chief Science Officer at Shenzhen Beike Biotechnology Co. Ltd.,( http://www.beikebiotech.com ), spoke at a conference on Hig
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,
Breaking Biology Technology:Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9
...hows naturally occurring antibodies contained in, ...for Alzheimer,s disease, CHICAGO, April 15 The U...axter International Inc. (NYSE: BAX ) today,annou...tural antibodies,contained in GAMMAGARD LIQUID [Im... as KIOVIG in the European Union, a plasma-derived...
.../PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,(...sentation by Dr.,Chandini Thirukkumaran of the Tom... Multiple Myeloma with Oncolytic Viral Therapy" wa...Cancer Research (AACR) Annual,Meeting. The meeting...,12-16, 2008., The presentation covered preclinic...
... CryoPort, Inc. (OTC,Bulletin Board: CYRX) (http...ent,community through their personal profile on My...he dynamic profile will include interviews with co...ent, and links to recent press., Visit CryoPort,.../profile.php?ID=19849 . Stay updated about CryoPo...
Other Biology Technology:Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 2Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 3Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 4Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 5Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Multiple Myeloma at AACR Annual Meeting 2CryoPort Creates Personal Wall on Wallst.net's Financial Social Community, my.wallst.net 2
(Date:12/4/2009)UVALDE Dr. Daniel Leskovar, a Texas AgriLife Research plant physiologist at the Texas AgriLife Research and Extension Center in Uvalde, has been investigating ways to help vegetable plants make a les
(Date:12/4/2009)The electroencephalogram (EEG) is widely used by physicians and scientists to study brain function and to diagnose neurological disorders. However, it has remained largely unknown whether the electrod
(Date:12/3/2009)WALL, N.J., Dec. 3 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in wireless public safety and finger-based biometric identification solutions, announced that a majority of its sha
Breaking Biology News(10 mins):Texas AgriLife researchers helping 2Texas AgriLife researchers helping 3Texas AgriLife researchers helping 4How to read brain activity? 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3Warner Chilcott to Hold 2009 Annual General Meeting of Shareholders and Special Court Ordered Meeting of Shareholders 50160 1Warner Chilcott to Hold 2009 Annual General Meeting of Shareholders and Special Court Ordered Meeting of Shareholders 50160 2Align Technology Announces Jury Verdict in Patent Litigation With Ormco Corporation 50156 1Align Technology Announces Jury Verdict in Patent Litigation With Ormco Corporation 50156 2Immucor Responds To FDA Notice 12802 1Immucor Responds To FDA Notice 12802 2
... signs of spring, like budding trees, are worth ce...mergence of fertile, winged termites swarming furi... them. , In New Orleans, as the swirling, airborn...archers with the Agricultural Research Service (AR...omeday knock down large numbers of Formosan subter...
...r imaging technologies allow physicians to visuali...tecting small blood clots not previously seen, but...,s outcome, a new study suggests. , The study incl...m. About half of the patients (98) had a multidete...gle-detector CT examination. The radiology examina...
...School of Medicine scientists have created the fir... possibly prevent the onset of a brain disease in ...indings, published online this week in the journal...velopment of a vaccine to prevent a group of fatal...cles called prions. , Although no cure for these d...
Other Biology News:Fungus Effective Against Winged Termites 2Newer imaging techniques may lead to over-treatment 2Active Vaccine Prevents Mice From Developing Prion Disease 2Active Vaccine Prevents Mice From Developing Prion Disease 3
GIBCO Dulbecco's Phosphate-Buffered Saline (D-PBS) (1X) liquid from Invitrogen
Rabbit Anti-LSD1 / BHC110 Antibody, Unconjugated from Upstate
Dulbecco's Phosphate-Buffered Saline (D-PBS) powder from Invitrogen
Rabbit Anti-CUGBP2 Monoclonal Antibody, Unconjugated, Clone PADZMD.495 from Invitrogen
Biology Products: